ライフサイエンスコーパス: vein thrombosis

1 enous thrombosis (122 VTE and 29 superficial vein thrombosis).

2 present in 62.5% of the patients with portal vein thrombosis.

3 d bloodstream infection and symptomatic deep-vein thrombosis.

4 unprovoked VTE, pulmonary embolism, and deep-vein thrombosis.

5 hrodysesthesia, cerebral ischaemia, and deep-vein thrombosis.

6 was no incidence of hepatic artery or portal vein thrombosis.

7 between extrapulmonary tuberculosis and deep vein thrombosis.

8 ombus organization in a murine model of deep vein thrombosis.

9 and PAD4 as potential drug targets for deep vein thrombosis.

10 e source of the prothrombotic effect in deep vein thrombosis.

11 deceased donor liver transplant for hepatic vein thrombosis.

12 hage, retroperitoneal collaterals, and renal vein thrombosis.

13 eminated tuberculosis complicated by splenic vein thrombosis.

14 endent risk factor for pre-transplant portal vein thrombosis.

15 use of unexpected acute rejection and portal vein thrombosis.

16 of such diseases as atherosclerosis and deep vein thrombosis.

17 association between JAK2 V617F and abdominal vein thrombosis.

18 % mortality, 43.7% disability, and 9.8% deep vein thrombosis.

19 Three (2.9%) grafts were lost due to portal vein thrombosis.

20 led to a complete resolution of the splenic vein thrombosis.

21 ism manifested as pulmonary embolism or deep vein thrombosis.

22 age, sex, treatment, tumor size, and portal vein thrombosis.

23 or placebo stockings) in patients with deep vein thrombosis.

24 ay less than 2 days, or had preexisting deep vein thrombosis.

25 st thrombotic syndrome in patients with deep vein thrombosis.

26 alysed were mortality and recurrence of deep vein thrombosis.

27 ism (0.43%; range, 0.26%-0.66%), superficial vein thrombosis (0.44%; range, 0.28%-0.68%), and cerebro

28 te chest syndrome (5), pneumonia (2), portal vein thrombosis (1), priapism (1), hemolytic uremic synd

29 The annual rates of deep vein thrombosis (1.46%; range, 1.15%-1.82%), pulmonary e

30 possibly associated with TRF-budesonide-deep vein thrombosis (16 mg/day) and unexplained deterioratio

31 ainly rejected for comorbidity (19%), portal vein thrombosis (16%), previous surgery (9%), obesity (9

32 atric surgery, 17 (0.3%) had portomesenteric vein thrombosis, 16 after sleeve gastrectomy and 1 follo

33 n OPV than in cirrhosis: extrahepatic portal vein thrombosis (18 [43%] of 42 vs five [12%] of 42); in

34 tent hemodialysis (2B); prophylaxis for deep vein thrombosis (1B); use of stress ulcer prophylaxis to

35 nce of heterogeneity between effects on deep vein thrombosis (266 versus 311, OR 0.85, 95% CI 0.72-1.

36 ving TASQ versus 10% receiving placebo; deep vein thrombosis (4% v 0%) was more common in the TASQ ar

37 thromboembolic events (6/11), that is, deep vein thrombosis (4), transitory ischemic attacks (2), pu

38 lower for pulmonary embolism (54%) and deep-vein thrombosis (44%) than heart attack (88%) and stroke

39 n grade three or higher toxicities were deep-vein thrombosis, 57 (26%) of 223 versus 27 (12%) of 220

40 ive than no IPC prophylaxis in reducing deep vein thrombosis (7.3% versus 16.7%; absolute risk reduct

41 pulmonary embolism, 1% (29 of 2327) for deep vein thrombosis, 7% (61 of 866) for sepsis, 16% (222 of

42 ractice adherence for the prevention of deep vein thrombosis (99% vs 85%, respectively; OR, 15.4 [95%

43 offer patients with symptomatic superficial-vein thrombosis a less burdensome and less expensive ora

44 lly, complications (pulmonary embolism, deep vein thrombosis, acute respiratory distress syndrome, pn

45 tus of FHMI were highest for unprovoked deep vein thrombosis (adjusted hazard ratio, 1.69; 95% confid

46 mbus and plasma of baboons subjected to deep vein thrombosis, an example of inflammation-enhanced thr

47 The FN rate was 1.14% (8/701; 7 deep vein thrombosis and 1 PE) for pooled normal, very low pr

48 l interpretations versus 1.5% (9/585, 5 deep vein thrombosis and 4 PE) in trinary interpretations (P

49 ficacy outcomes in patients with superficial-vein thrombosis and additional risk factors given either

50 ss this, we adopted a stenosis model of deep vein thrombosis and analyzed venous thrombi in peptidyla

51 embolic deterrent stockings in reducing deep vein thrombosis and appeared to be as effective as pharm

52 ulmonary embolism associated with lower-limb vein thrombosis and at least 1 criterion for severity we

53 bute to pathologies, including arterial/deep vein thrombosis and atherosclerosis.

54 techniques (compression ultrasound for deep-vein thrombosis and computed tomography pulmonary angiog

55 nary embolism indication, patients with deep-vein thrombosis and concomitant pulmonary embolism were

56 sms occurred, including six symptomatic deep vein thrombosis and four pulmonary emboli, resulting in

57 and inflammatory activity of T cells in deep vein thrombosis and its consequences for venous thrombus

58 3%) patients developed pre-transplant portal vein thrombosis and its presence had no impact in the ov

59 rst occurrence of pulmonary embolism or deep-vein thrombosis and performed analyses of the data on an

60 source thrombi and culprit emboli after deep vein thrombosis and pulmonary embolism (DVT-PE).

61 In many patients with deep vein thrombosis and pulmonary embolism (venous thromboem

62 Deep vein thrombosis and pulmonary embolism are major health

63 e initial 5 to 10 days of treatment for deep vein thrombosis and pulmonary embolism as well as for lo

64 e initial 5 to 10 days of treatment for deep vein thrombosis and pulmonary embolism as well as for lo

65 prise the major arterial thromboses and deep-vein thrombosis and pulmonary embolism comprise venous t

66 e treatment and secondary prevention of deep-vein thrombosis and pulmonary embolism has been shown in

67 of heparin thromboprophylaxis decreases deep vein thrombosis and pulmonary embolism in medical-surgic

68 Because the clinical diagnosis of deep-vein thrombosis and pulmonary embolism is nonspecific, i

69 31, 2004, and in which risk factors for deep vein thrombosis and pulmonary embolism were assessed.

70 venous thromboembolism (which includes deep vein thrombosis and pulmonary embolism), but the evidenc

71 and Measures: Rates of symptomatic VTE (deep vein thrombosis and pulmonary embolism, confirmed by dup

72 d and unprovoked events, as well as for deep vein thrombosis and pulmonary embolism.

73 ancer patients are at increased risk of deep vein thrombosis and pulmonary embolism.

74 mortality and morbidity associated with deep vein thrombosis and pulmonary embolism.

75 Superficial-vein thrombosis can lead to deep-vein thrombosis and pulmonary embolism.

76 gents are the mainstay of treatment for deep vein thrombosis and pulmonary embolism.

77 as a composite of asymptomatic proximal deep-vein thrombosis and symptomatic venous thromboembolism.

78 nd included serious adverse events (eg, deep vein thrombosis and systemic complications) and minor ad

79 osis of proximal or inferior vena caval deep vein thrombosis and treated with CDT from 2005 to 2010.

80 ween FHMI and VTE applied to unprovoked deep vein thrombosis and was not explained by modifiable athe

81 ked proximal and distal deep and superficial vein thrombosis and women in the upper quartile of lupus

82 Two donors developed portal vein thrombosis, and 1 had inferior vena caval thrombosi

83 A total of 4921 patients presented with deep-vein thrombosis, and 3319 with a pulmonary embolism.

84 spitalized for proximal lower-extremity deep vein thrombosis, and 3649 patients (4.1%) underwent CDT.

85 embolism, 25 (22%) had a superior mesenteric vein thrombosis, and 4 (3%) had superior mesenteric arte

86 h an objectively confirmed diagnosis of deep-vein thrombosis, and an indication to receive anticoagul

87 torenal syndrome, hepatichydrothorax, portal vein thrombosis, and Budd-Chiari syndrome.

88 Preoperative albumin, postoperative deep-vein thrombosis, and electrolyte levels were associated

89 nts were one event each of hypotension, deep vein thrombosis, and hypophosphatemia.

90 is Child-Pugh score, presence of HCC, portal vein thrombosis, and lack of secondary prophylaxis were

91 re, urinary tract infection, pneumonia, deep vein thrombosis, and myocardial infarction were independ

92 or venous thromboembolism, proximal leg deep vein thrombosis, and pulmonary embolism developing durin

93 ons, including deep venous thrombosis, renal vein thrombosis, and pulmonary embolism.

94 respiratory failure, pulmonary embolism/deep vein thrombosis, and sepsis) after selected operations.

95 e cancer, hypertension, hyperlipidemia, deep-vein thrombosis, and stroke.

96 C filter vs IVC filter on PE, fatal PE, deep vein thrombosis, and/or mortality in trauma patients.

97 sm, progression or recurrence of superficial vein-thrombosis, and all-cause mortality at 45 days in t

98 sm, progression or recurrence of superficial vein-thrombosis, and all-cause mortality, and was not as

99 tions included warfarin (presumably for deep-vein thrombosis), antihypertensive agents, and a statin.

100 me was the composite of any symptomatic deep-vein thrombosis, any nonfatal pulmonary embolism, and de

101 Outcomes for graft and deep vein thrombosis are not favorable.

102 artery on the same side as the isolated calf vein thrombosis as well as on the opposite side.

103 ciated with an increased incidence of portal-vein thrombosis, as compared with placebo.

104 hrombosis, or asymptomatic proximal-leg deep-vein thrombosis, as detected with the use of systematic

105 Portal vein thrombosis at listing was not associated with lower

106 Portal vein thrombosis at LT is associated with early (90 days)

107 lecystitis, pancreatitis, hemorrhage, portal vein thrombosis, bowel wall perforation, or dehydration.

108 ference in the primary end point of leg deep-vein thrombosis but a reduced rate of pulmonary embolus

109 and are believed to reduce the risk of deep vein thrombosis by 40%.

110 Superficial-vein thrombosis can lead to deep-vein thrombosis and pul

111 ion in risk of the specific endpoint of deep vein thrombosis compared with no statin use (RR 0.77, 95

112 ality, ventilator-associated pneumonia, deep vein thrombosis, depression, and hostility.

113 ntly develops in patients with proximal deep-vein thrombosis despite treatment with anticoagulant the

114 n-interventional study of patients with deep-vein thrombosis, done in hospitals and community care ce

115 r-old German-Caucasian man arrived with deep vein thrombosis DVT, pain, oedema and rubor of right low

116 TEEs included deep vein thrombosis (DVT) alone in 49.7%, pulmonary embolus

117 RATIONALE: Deep vein thrombosis (DVT) and its complication pulmonary emb

118 Deep vein thrombosis (DVT) and its complication, pulmonary em

119 ully selected patients with cancer with deep vein thrombosis (DVT) and low-risk pulmonary embolism.

120 enous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a

121 enous thromboembolism (VTE), comprising deep vein thrombosis (DVT) and pulmonary embolism (PE), is a

122 ely may be at higher risk of developing deep vein thrombosis (DVT) and pulmonary embolism (PE).

123 Deep vein thrombosis (DVT) and pulmonary embolism are collect

124 Deep vein thrombosis (DVT) and pulmonary embolism are common

125 oring for TEE and assessment of risk of deep vein thrombosis (DVT) by the Wells prediction rule were

126 curate detection of recurrent same-site deep vein thrombosis (DVT) is a challenging clinical problem.

127 Deep vein thrombosis (DVT) is a major cause of cardiovascular

128 ment of suspected ipsilateral recurrent deep vein thrombosis (DVT) is a major clinical challenge beca

129 Deep-vein thrombosis (DVT) is regarded a chronic disease as i

130 Deep vein thrombosis (DVT) isolated to the calf veins (distal

131 ulants in patients with cancer who have deep vein thrombosis (DVT) of the lower limbs.

132 hs) and objectively documented proximal deep vein thrombosis (DVT) or pulmonary embolism, with a life

133 Both IPC and GCS are recommended for deep vein thrombosis (DVT) prophylaxis in surgical patients.

134 on on the use of compression devices as deep vein thrombosis (DVT) prophylaxis methods in orthopedic

135 (4) deep vein thrombosis (DVT) prophylaxis was independent of hig

136 Enoxaparin sodium is widely used for deep vein thrombosis (DVT) prophylaxis, yet DVT rates remain

137 utation poses a clearly higher risk for deep-vein thrombosis (DVT) than for pulmonary embolism.

138 Deep vein thrombosis (DVT) with its major complication, pulmo

139 ower the risk of pulmonary embolism and deep vein thrombosis (DVT), although a cause-effect relations

140 patients with suspected lower extremity deep vein thrombosis (DVT), compression ultrasound (CUS) is t

141 first unprovoked isolated distal (calf) deep vein thrombosis (DVT), has a low risk of recurrence and

142 3.6%) patients; PE, in 237 (11.4%); and deep vein thrombosis (DVT), in 121 (5.8%).

143 The rates of deep vein thrombosis (DVT), pulmonary embolism (PE), and VTE

144 l clot properties can predict recurrent deep vein thrombosis (DVT), we studied 320 consecutive patien

145 ution in humans after acute symptomatic deep vein thrombosis (DVT).

146 ombotic syndrome (PTS) in patients with deep vein thrombosis (DVT).

147 icial thrombosis and the development of deep vein thrombosis (DVT).

148 as a complimentary approach to isolated calf vein thrombosis (DVT).

149 ty, all-cause mortality, and subsequent deep vein thrombosis (DVT).

150 asia/VLG) after initiating treatment of deep-vein thrombosis (DVT); in 8 patients, cancer was not kno

151 oup, and grade 2 thrombosis and grade 2 deep vein thrombosis, each in one patient in the chemotherapy

152 e liver in children with extrahepatic portal vein thrombosis (EHPVT), with surgical outcome after Mes

153 Eligible patients with deep-vein thrombosis (EINSTEIN-DVT) or pulmonary embolism (EI

154 The prevalence of deep vein thrombosis following decannulation from extracorpor

155 years or older with symptomatic superficial-vein thrombosis from 27 sites (academic, community hospi

156 Budd-Chiari syndrome (BCS) and portal vein thrombosis have been reported to be associated with

157 Risk factors for deep-vein thrombosis have been shown not to be always the sam

158 g week lowered the risk of proximal leg deep vein thrombosis (hazard ratio, 0.46; 95% CI, 0.27-0.77;

159 a predictor for developing proximal leg deep vein thrombosis (hazard ratio, 1.25; 95% CI, 1.06-1.46;

160 s of treated HIV-infected patients with deep vein thrombosis, hepatitis C, renal impairment, thyroid

161 I], 0.51-0.90; P=0.008), including both deep-vein thrombosis (HR, 0.66; 95% CI, 0.47-0.92; P=0.01) an

162 pliteal leg deep veins (isolated distal deep vein thrombosis [IDDVT]) are frequently diagnosed in sub

163 ent in 4 requiring correction and subclavian vein thrombosis in 1 patient.

164 ed to characterize the pre-transplant portal vein thrombosis in a cohort of liver transplant recipien

165 Principal outcomes were deep vein thrombosis in both the lower and upper extremities,

166 to fondaparinux for treatment of superficial-vein thrombosis in terms of symptomatic deep-vein thromb

167 ymptomatic, radiographically confirmed, deep-vein thrombosis in the arm or leg or pulmonary embolism.

168 The prevalence of deep vein thrombosis in the cannulated vessel following extra

169 ibe the prevalence of postdecannulation deep vein thrombosis in the cannulated vessel in adults who h

170 -sided PICC were more likely to develop deep-vein thrombosis in the ipsilateral arm (HR 3.37, 95% CI

171 significantly more likely to develop a deep-vein thrombosis in the ipsilateral arm compared with the

172 The use of thrombolysis for occlusive deep vein thrombosis, in attempt to reduce the long-term comp

173 seminated intravascular coagulation and deep vein thrombosis, in tuberculosis (TB) patients.

174 2; 95% confidence interval, 1.77-2.79), deep vein thrombosis (incidence rate ratio, 1.92; 95% confide

175 ics Trial (GIFT) of Warfarin to Prevent Deep Vein Thrombosis included patients aged 65 years or older

176 However, the risk of subsequent deep vein thrombosis increased by 50% among VCF patients with

177 In contrast, in a model of vein thrombosis induced by flow restriction in the infer

178 e the thrombus and vein wall rapidly on deep vein thrombosis induction and remain in the tissue throu

179 Portal vein thrombosis is a frequent complication in end-stage

180 Deep vein thrombosis is a major global health issue, responsi

181 symptomatic central venous line-related deep vein thrombosis is associated with worse outcomes, parti

182 tment of acute proximal lower-extremity deep vein thrombosis is increasing in the United States and h

183 Portomesenteric vein thrombosis is rare after laparoscopic bariatric sur

184 is', 'necrobacillosis', or 'internal jugular vein thrombosis', is a rare but serious emerging infecti

185 For patients with acute iliofemoral deep vein thrombosis, it remains unclear whether the addition

186 ts with Budd-Chiari syndrome and with portal vein thrombosis, Kiladjian et al observed that JAK2V617F

187 Pediatric lower extremity deep vein thrombosis (LE-DVT) can lead to postthrombotic synd

188 The secondary complication of adrenal vein thrombosis leading to bilateral adrenal hemorrhage

189 onary embolism at 6 months, symptomatic deep vein thrombosis, major bleeding, death at 3 and 6 months

190 tors of PE (obesity, pregnancy, cancer, deep vein thrombosis, major procedure, spinal cord paralysis,

191 artery disease, obesity, hypertension, deep vein thrombosis, male sex, high-sensitivity C-reactive p

192 h membranous nephropathy may be due to renal vein thrombosis, malignant hypertension, or an additiona

193 lity in the developed world, underlying deep vein thrombosis, myocardial infarction, and stroke.

194 5), nausea (n = 2), chest pain (n = 2), deep vein thrombosis (n = 1), transaminitis (n = 1), and dehy

195 iated with hepatic artery (n = 15) or portal vein thrombosis (n = 14).Mean surgical time was 11.33 +/

196 erse events (n = 7), cataracts (n = 4), deep vein thrombosis (n = 3), cerebral infarction (n = 2), he

197 cacy end point was the composite of any deep vein thrombosis, nonfatal pulmonary embolism, or all-cau

198 ith non-BCS liver recipients), one of portal vein thrombosis (nonsignificant [NS]), and one of portal

199 atheter-related blood stream infection, deep vein thrombosis, occlusion, pain, infiltration, bleeding

200 The primary end point plus superficial-vein thrombosis occurred in 4.4% of patients in the low-

201 Deep vein thrombosis occurred in 5 patients.

202 Early graft loss from renal vein thrombosis occurred in two singly implanted kidneys

203 Obesity is a risk factor for deep vein thrombosis of the leg and pulmonary embolism.

204 inar, we discuss pulmonary embolism and deep vein thrombosis of the legs.

205 to 1.45; P=0.42), whereas the rates of deep-vein thrombosis only were 0.09 and 0.20, respectively (h

206 t least 18 years with acute symptomatic deep-vein thrombosis or acute symptomatic pulmonary embolism

207 romboembolism defined as a composite of deep vein thrombosis or non-fatal or fatal pulmonary embolism

208 FN study was defined as development of deep vein thrombosis or PE within 3 months after a negative b

209 dependent of the presence or absence of deep vein thrombosis or pulmonary embolism at the time of IVC

210 ant drugs and SFJ ligation); subsequent deep-vein thrombosis or pulmonary embolism occurred in 9.3% (

211 inflammatory bowel disease who develop deep vein thrombosis or pulmonary embolism often have active

212 use of medical resources; no subsequent deep-vein thrombosis or pulmonary embolism was observed in fo

213 Documented VTE (including deep vein thrombosis or pulmonary embolism) and unprovoked VT

214 tcome was VTE (defined as patients with deep vein thrombosis or pulmonary embolism) that occurred dur

215 rebrovascular accident), venous events (deep vein thrombosis or pulmonary embolism), and respiratory

216 one or more dose received, presence of deep vein thrombosis or pulmonary embolism, or assessment for

217 vein thrombosis in terms of symptomatic deep-vein thrombosis or pulmonary embolism, progression or re

218 outcome was a composite of symptomatic deep-vein thrombosis or pulmonary embolism, progression or re

219 med with compression ultrasound showing deep vein thrombosis or with chest CT showing pulmonary embol

220 10% [67/690]; p=0.92) or recurrence of deep vein thrombosis (OR 0.93 [95% CI 0.66-1.31]; 6.4% [70/10

221 re associated with an increased risk of deep vein thrombosis (OR 2.55, 1.54-4.23, p<0.0001) but not p

222 bolism, pulmonary embolism, symptomatic deep-vein thrombosis, or asymptomatic proximal-leg deep-vein

223 statin use with venous thromboembolism, deep vein thrombosis, or pulmonary embolism in adults were in

224 llected data on venous thromboembolism, deep vein thrombosis, or pulmonary embolism outcomes.

225 events (myocardial infarction, stroke, deep vein thrombosis, or pulmonary embolism) and haemorrhagic

226 P = 0.007), disability (P = 0.012), and deep vein thrombosis (P = 0.048).

227 compared with placebo reduced rates of deep vein thrombosis (pooled risk ratio, 0.51 [95% CI, 0.41,

228 erences in hepatic artery thrombosis, portal vein thrombosis, primary nonfunction, and biliary strict

229 antithrombotics (91.46% versus 97.04%), deep vein thrombosis prophylaxis (73.79% versus 89.54%), disc

230 onfidence interval [CI], 0.77 to 0.91), deep vein thrombosis prophylaxis (OR, 0.88; 95% CI, 0.83 to 0

231 improve compliance with antibiotic and deep vein thrombosis prophylaxis, and improve overall percept

232 gement, neurology consultation, Holter, deep vein thrombosis prophylaxis, oral hypoglycemic intensifi

233 catheter removal, R = -0.089 [P = .63]; deep vein thrombosis prophylaxis, R = 0.101 [P = .59]).

234 re documentation, lipid management, and deep vein thrombosis prophylaxis.

235 l complications (myocardial infarction, deep vein thrombosis, pulmonary embolism, and pneumonia).

236 acute renal failure requiring dialysis, deep vein thrombosis, pulmonary embolism, sepsis, pneumonia,

237 3 to 5 nonhematologic toxicity included deep vein thrombosis/pulmonary embolism (21%), hemorrhage (7%

238 ), whereas most venous studies examined deep vein thrombosis/pulmonary embolus prevention (42%) or ve

239 oup (ECOG), presence of cirrhosis and portal vein thrombosis (PVT) (none, branch, and main).

240 Portal vein thrombosis (PVT) and different cardiovascular disor

241 ts of liver cirrhosis associated with portal vein thrombosis (PVT) can be effectively treated by tran

242 In cirrhosis, portal vein thrombosis (PVT) could be a cause or a consequence

243 lecular-weight heparin, in preventing portal vein thrombosis (PVT) in patients with advanced cirrhosi

244 Portal vein thrombosis (PVT) is common in patients with cirrhos

245 Nonneoplastic portal vein thrombosis (PVT) is frequent in patients with cirrh

246 survival of hepatocellular carcinoma portal vein thrombosis (PVT) patients treated with (90)Y-loaded

247 nts with Child-Pugh B disease who had portal vein thrombosis (PVT) survived 5.6 months (95% confidenc

248 e hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) treated with (90)Y radioembolizati

249 ith no significant difference between portal vein thrombosis (PVT) versus no PVT (7 versus 13 months)

250 The 1-year probability of developing portal vein thrombosis (PVT) was 9%, and 53% of patients receiv

251 with chronic noncirrhotic, nontumoral portal vein thrombosis (PVT), the usually recommended strategy

252 ar carcinoma (HCC), including 16 with portal vein thrombosis (PVT), were treated with (90)Y-loaded gl

253 (BCS) and nonmalignant, noncirrhotic portal vein thrombosis (PVT).

254 from portal hypertension but also by portal vein thrombosis (PVT).

255 With the baseline PICC-related deep vein thrombosis rate of 2.7% and pooled OR of 2.55, the

256 RR, 4.30 95% CI, 1.60-11.54) and higher deep vein thrombosis rates (2.94 1.35-6.38).

257 enic reporter mice, we demonstrate that deep vein thrombosis-recruited TEM receive an immediate antig

258 sis of 11 studies comparing the risk of deep vein thrombosis related to PICCs with that related to CV

259 axis to IPC further reduced the risk of deep vein thrombosis (relative risk, 0.54; 95% CI, 0.32-0.91;

260 nificant difference in the incidence of deep vein thrombosis (relative risk, 1.76 [95% CI, 0.50-6.19]

261 Deep vein thrombosis remains a major health problem necessita

262 st thrombotic syndrome in patients with deep vein thrombosis remains unknown.

263 illation, supraventricular tachycardia, deep vein thrombosis, respiratory depression, atelectasis, pn

264 .97]; p=0.04; I=0%) but not symptomatic deep vein thrombosis (risk ratio, 0.86 [95% CI, 0.59, 1.25];

265 0.74, 1.08]; p=0.26; I=0%), symptomatic deep vein thrombosis (risk ratio, 0.87 [95% CI, 0.60, 1.25];

266 8 [95% CI, 0.34, 0.97]; p=0.04) but not deep vein thrombosis (risk ratio, 0.90 [95% CI, 0.74, 1.08];

267 We evaluated the role of residual vein thrombosis (RVT) to assess the optimal duration of

268 ical patients with platelet activation (deep vein thrombosis; saphenous vein graft occlusion after co

269 Deep vein thrombosis screening was performed using a rigorous

270 served in rates of postoperative ileus, deep vein thrombosis, small bowel obstruction, urinary strict

271 eagues report on the relevance of splanchnic vein thrombosis (SVT) as a marker of occult malignant di

272 tly, it has become apparent that superficial vein thrombosis (SVT) can have serious complications.

273 Superficial vein thrombosis (SVT) increases the risk of venous throm

274 Antithrombotic treatment of splanchnic vein thrombosis (SVT) is a clinical challenge.

275 , acute, symptomatic, lower-limb superficial-vein thrombosis (SVT) is debated.

276 Subclavian vein thrombosis (SVT) is usually caused by vigorous acti

277 JAK2V617F screening in splanchnic vein thrombosis (SVT) patients without typical hematolog

278 ombosis following a diagnosis of superficial vein thrombosis (SVT).

279 y efficacy outcome was the composite of deep-vein thrombosis (symptomatic or asymptomatic detected by

280 omposite of symptomatic or asymptomatic deep vein thrombosis, symptomatic pulmonary embolism, or fata

281 Cs are associated with a higher risk of deep vein thrombosis than are CVCs, especially in patients wh

282 urysmal subarachnoid hemorrhage and cerebral vein thrombosis, that are predominant in women.

283 Among patients with acute proximal deep-vein thrombosis, the addition of pharmacomechanical cath

284 es), pulmonary embolus (two cases), and deep-vein thrombosis (three cases).

285 signed 692 patients with acute proximal deep-vein thrombosis to receive either anticoagulation alone

286 rial of patients with acute iliofemoral deep vein thrombosis treated with a fixed-dose catheter throm

287 terization of pediatric upper extremity deep vein thrombosis (UE-DVT) and of UE postthrombotic syndro

288 ular carcinoma (HCC) with and without portal vein thrombosis underwent radioembolization with Yttrium

289 e thrombotic vein, we identify a set of deep vein thrombosis upregulated cytokines and chemokines tha

290 the weighted frequency of PICC-related deep vein thrombosis was highest in patients who were critica

291 Portal vein thrombosis was independently associated with increa

292 Deep vein thrombosis was induced in the inferior vena cava of

293 Portal vein thrombosis was present in 11 patients (6%).

294 prised events of pulmonary embolism and deep-vein thrombosis) was more common in the PFO closure grou

295 atic pulmonary embolism with or without deep-vein thrombosis, we compared rivaroxaban (15 mg twice da

296 ned high-risk patients, 20 asymptomatic deep vein thrombosis were detected with venous duplex ultraso

297 ears, 52% women) with acute iliofemoral deep vein thrombosis were randomized to receive ultrasound-as

298 tic pulmonary embolism (with or without deep-vein thrombosis) were assigned to receive edoxaban 60 mg

299 ars; range, 32-75 years) with HCC and portal vein thrombosis who were examined with both contrast mat

300 icoagulant therapy for the treatment of deep-vein thrombosis, without the need for laboratory monitor